Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition

Panagiotis J. Vlachostergios; Maria Papathanassiou; Maria Anagnostou; Eleni Thodou; Ioannis Tamposis; Lampros Mitrakas; Ioannis Zachos; Maria Ioannou; George K. Koukoulis; Maria Samara; Vassilios Tzortzis

doi:10.12688/f1000research.136087.1

Home Browse Mutational profile of primary clear cell renal cell carcinoma predicts...

ALL Metrics

Views

Downloads

Get PDF

Get XML

Export

▬

✚

Brief Report

Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition

[version 1; peer review: 1 approved, 1 approved with reservations]

Panagiotis J. Vlachostergios ^1-3, Maria Papathanassiou⁴, Maria Anagnostou⁴, [...] Eleni Thodou⁴, Ioannis Tamposis⁵, Lampros Mitrakas³, Ioannis Zachos³, Maria Ioannou⁴, George K. Koukoulis⁴, Maria Samara⁴, Vassilios Tzortzis³

Panagiotis J. Vlachostergios ^1-3, Maria Papathanassiou⁴, [...] Maria Anagnostou⁴, Eleni Thodou⁴, Ioannis Tamposis⁵, Lampros Mitrakas³, Ioannis Zachos³, Maria Ioannou⁴, George K. Koukoulis⁴, Maria Samara⁴, Vassilios Tzortzis³

PUBLISHED 01 Aug 2023

Author details Author details

¹ Hematology & Medical Oncology, Weill Cornell Medicine, New York, New York, USA
² Medical Oncology, IASO Thessalias Hospital, Larissa, Thessalia, Greece
³ Urology, University of Thessaly, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, Larissa, Thessalia, Greece
⁴ Pathology, University of Thessaly, Faculty of Medicine, School of Health Sciences, Larissa, Greece
⁵ Computer Science and Biomedical Informatics, University of Thessaly, Lamia, Greece

Panagiotis J. Vlachostergios
Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Maria Papathanassiou
Roles: Data Curation, Formal Analysis, Funding Acquisition, Investigation, Writing – Original Draft Preparation

Maria Anagnostou
Roles: Data Curation, Investigation, Writing – Original Draft Preparation

Eleni Thodou
Roles: Investigation, Writing – Review & Editing

Ioannis Tamposis
Roles: Funding Acquisition, Investigation, Methodology, Resources, Software, Writing – Review & Editing

Lampros Mitrakas
Roles: Investigation, Methodology, Writing – Review & Editing

Ioannis Zachos
Roles: Investigation, Resources, Writing – Review & Editing

Maria Ioannou
Roles: Investigation, Resources, Writing – Review & Editing

George K. Koukoulis
Roles: Investigation, Resources, Writing – Review & Editing

Maria Samara
Roles: Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Vassilios Tzortzis
Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing

OPEN PEER REVIEW

REVIEWER STATUS

This article is included in the Oncology gateway.

This article is included in the HEAL1000 gateway.

Abstract

Background: The risk of recurrence after nephrectomy for primary clear cell renal cell carcinoma (ccRCC) is estimated in daily practice solely based on clinical criteria. The aim of this study was to assess the prognostic relevance of common somatic mutations with respect to tumor aggressiveness and outcomes of ccRCC patients after definitive treatment.
Methods: Primary tumors from 37 patients with ccRCC who underwent radical nephrectomy were analyzed for presence of somatic mutations using a 15-gene targeted next-generation sequencing (NGS) panel. Associations to histopathologic characteristics and outcomes were investigated in the study cohort (n=37) and validated in The Cancer Genome Atlas (TCGA) ccRCC cohort (n=451).
Results: VHL was the most frequently mutated gene (51%), followed by PBRM1 (27%), BAP1 (13%), SETD2 (13%), KDM5C (5%), ATM (5%), MTOR (5%), and PTEN (3%). One-third of patients did not have any somatic mutations within the 15-gene panel. The vast majority of tumors harboring no mutations at all or VHL-only mutations (51%) were more frequently of smaller size (pT1-2) and earlier stage (I/II), whereas presence of any other gene mutations in various combinations with or without VHL was enriched in larger (pT3) and higher stage tumors (III) (p=0.02). No recurrences were noted in patients with unmutated tumors or VHL-only mutations as opposed to three relapses in patients with non-VHL somatic mutations (p=0.06). Presence of somatic mutations in PBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, or PTEN genes in 451 TCGA ccRCC patients was associated with a significantly shorter disease-free survival (DFS) compared to those with unaltered tumors (q=0.01).
Conclusions: Preliminary findings from this ongoing study support the prognostic value of non-VHL mutations including PBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, and PTEN in primary ccRCC tumors as surrogates of earlier recurrence and potential selection for adjuvant immune checkpoint inhibition.

Keywords

clear cell, kidney cancer, renal cell carcinoma, recurrence, immune checkpoint inhibition, genomics, mutational profile, next generation sequencing

Corresponding author: Panagiotis J. Vlachostergios

Competing interests: No competing interests were disclosed.

Grant information: This work was funded by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH—CREATE—INNOVATE, project code: T2EDK-03079.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2023 Vlachostergios PJ et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite: Vlachostergios PJ, Papathanassiou M, Anagnostou M et al. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2023, 12:918 (https://doi.org/10.12688/f1000research.136087.1) First published: 01 Aug 2023, 12:918 (https://doi.org/10.12688/f1000research.136087.1) Latest published: 14 Jun 2024, 12:918 (https://doi.org/10.12688/f1000research.136087.2)

Introduction

Renal cell carcinoma (RCC) is a heterogenous group of kidney cancers originating from the nephron.¹ Renal cell carcinoma ranks among the ten most frequently diagnosed malignancies worldwide, with an estimated 400.000 new diagnoses and more than 170.000 deaths annually.²^,³ Clear cell RCC (ccRCC) is the most common RCC subtype, accounting for about 70-75% of cases and has a distinct molecular profile.¹^,⁴

Localized ccRCC is treated with surgical resection, either partial or radical nephrectomy. Nevertheless, one-third of these patients experience recurrence.⁵ So far, ccRCC recurrence, disease progression and mortality are being predicted using clinicopathological criteria.⁶ While various recurrence models have been proposed, they only marginally outperformed standard staging.⁷ Further, they demonstrate statistically significant variability in their predictive ability over time, rendering implementation into clinical practice and clinical trial design challenging.⁷

Immune checkpoint inhibition with the use of pembrolizumab, a monoclonal antibody against programmed death-1 (PD-1), is approved as adjuvant therapy for patients with resected ccRCC who have a high risk of recurrence.⁸ This was based on results of a phase III randomized double-blind study comparing pembrolizumab with placebo, which demonstrated a significant improvement in disease-free survival (DFS).⁹ Patient selection criteria for a high risk of recurrence included tumor stage II with nuclear grade 4 or sarcomatoid differentiation, tumor stage III or higher, regional lymph-node metastasis, or stage M1 without evidence of disease after combined nephrectomy and metastasectomy either concurrently or within a year from primary tumor resection.⁹

What currently remains an unmet need is the ability to predict which patients with ccRCC will relapse using a single or composite molecular biomarker that would be more directly related with tumor biology.

In this ongoing prospective study, we examined the mutational profile of patients with non-metastatic ccRCC who underwent nephrectomy, followed by observation or adjuvant immunotherapy with pembrolizumab depending on established clinical and histopathological criteria. We studied associations of mutated genes with high-risk features and assessed the prognostic relevance of somatic mutations with regard to DFS after nephrectomy with or without adjuvant immunotherapy.

Methods

Ethical considerations

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board and Ethics Committee of Faculty of Medicine, University of Thessaly (3214/29.07.2016) on 29 July 2016.

Study design

This was a prospective single-center cohort study of patients with a diagnosis of ccRCC who underwent radical nephrectomy followed by observation or adjuvant immune checkpoint inhibition with pembrolizumab at the University Hospital of Larissa between December 2020 and February 2023. Eligible subjects included patients of ≥18 years of age, with histologically confirmed non-metastatic ccRCC, without prior systemic therapy for RCC. Patients were eligible if they had an intermediate-to-high or high risk of recurrence based on histopathological features including pT2 with grade 4 or sarcomatoid differentiation, pT3 or pT4 with any grade, or any pT and grade with presence of positive lymph nodes (N+). Subjects unable to provide consent, those with low risk of recurrence or subjects receiving steroids at a daily dose above 10mg of prednisone for an active autoimmune or other condition were excluded from the study. The primary endpoint of the study was the percentage of patients without disease recurrence.

Data collection

Fresh frozen tissue samples were acquired from patients. Tumor tissue was acquired after surgical resection, cut in 5 mg cubes and stored in stabilization solution (RNA later, Thermo Fisher Scientific) at -80^oC freezer, after written informed consent was obtained. DNA extraction and quantification was performed from 5 mg of fresh-frozen tissue. Library preparation was conducted with the use of DNA AmpliSeq for Ion Torrent, with an input of 40 ng DNA per sample. Sample libraries were quantified with the use of Qubit (Thermo-Fisher Scientific) and real-time polymerase chain reaction (PCR), then sequenced on Ion Torrent S5 sequencer, using the Oncomine Kidney panel (Thermo-Fisher Scientific). Library amplification was conducted using the Library PLUS for Ion Torrent kit (Thermo Fisher). Library amplification included enzyme activation at 99^oC for 2 minutes, 16 cycles of denaturation at 99^oC for 15 seconds and annealing and extension steps at 60^oC for 4 minutes and a final hold step at 10^oC. The commercially available Oncomine^TM Kidney Panel (Thermo Fisher Scientific) provided the primer pairs used for library preparation. qPCR was conducted using the Ion Universal Library Quantitation Kit (Thermo Fisher Scientific). qPCR steps include an initial step of incubation at 50^oC for 2 minutes, a polymerase activation step at 95^oC for 2 minutes, 40 cycles of 95^oC for 15 seconds and 60^oC for 1 minute and a final hold step at 10^oC.¹⁰

Clinicopathological characteristics recorded for the analysis included patient age, sex, ISUP grade, tumor diameter, T-stage, presence of vascular invasion, presence of sarcomatoid differentiation, presence of necrosis, AJCC stage, and emergence of recurrent disease during follow up. Nephrectomy surgical specimens were reviewed by two independent pathologists from our institution.

A publicly available database, cBioportal for Cancer Genomics (accessed on 24 May 2023), was used to query DNA sequencing data for mutations in a prospective multicenter cohort from The Cancer Genome Atlas (TCGA) including 451 patients with ccRCC (accessed on 24 May 2023).

Data analysis

The following genes were analyzed for presence of somatic mutations: ATM, BAP1, KDM5C, MET, MTOR, NF2, PBRM1, PIK3CA, PTEN, SETD2, SMARCB1, TP53, TSC1, TSC2, and VHL. Variant calling was performed using the Ion Reporter Software (Thermo-Fisher Scientific). The Pearson’s Chi squared test was used to determine whether there was a statistically significant difference in clinicopathological characteristics and emergence of recurrence between subgroups of patients with distinct mutational profiles (unmutated or VHL-only mutated versus other gene mutations). Time-to-event outcomes (DFS) were estimated using the Kaplan-Meier method. Multiple hypothesis test correction was applied using the Benjamini–Hochberg method. All tests were two-sided, and p and q values ≤0.05 were considered statistically significant. The IBM SPSS v.22 software was used for the analysis.

Results

Mutations in non-VHL genes are associated with more aggressive disease

We first assessed the frequency of mutations in primary ccRCC tumors. In the discovery cohort (n=37), patients’ clinical and histopathological characteristics are described in Table 1. VHL was the most frequently mutated gene (n=19; 51%), followed by PBRM1 (n=10; 27%), BAP1 (n=5; 13%), SETD2 (n=5; 13%), KDM5C (n=2, 5%), ATM (n=2, 5%), MTOR (n=2, 5%), and PTEN (n=1, 3%) (Table 2). Variant types per gene are listed in the data file.²³ 11 patients (30%) did not have any somatic mutations within the 15-gene targeted panel.

Table 1. Clinical and histopathological characteristics of ccRCC patients (discovery cohort, n=37).

Characteristic	Number (%)
Age
median (range)	63 (42-87)
Sex
males	28 (75)
Tumor diameter (cm)
median (range)	5.6 (1.6 – 15)
Pathological T stage
T1	21 (57)
T2	6 (16)
T3	10 (27)
ISUP grade
2	13 (35)
3	15 (41)
4	8 (24)
Vascular invasion	5 (14)
Necrosis	13 (35)
Sarcomatoid differentiation	0
AJCC TNM stage
I	21 (57)
II	6 (16)
III	10 (27)

Table 2. Frequency of mutated genes in primary ccRCC tumors (discovery cohort, n=37).

Gene	Frequency, n (%)
VHL	19 (51)
PBRM1	10 (27)
BAP1	5 (13)
SETD2	5 (13)
KDM5C	2 (5)
ATM	2 (5)
MTOR	2 (5)
PTEN	1 (3)

Tumors harboring no mutations at all or only VHL mutations (n=19, 51%) were associated with smaller size (pT1-2 n=17, 89%) and earlier stage (I/II n=17; 89%), whereas presence of any other gene mutations in various combinations with or without VHL was enriched in larger (pT3, n=8; 44%; p=0.02) and more advanced tumors (III, n=8; 44%; p=0.02) (Table 3). There was also a trend towards higher frequency of ISUP grade, vascular invasion, and necrosis in these tumors (Table 3).

Table 3. Associations between histopathological characteristics and mutational profile (discovery cohort, n=37).

Variable	Mutated genes		P value
Variable	None or VHL-only	Non-VHL	P value
Pathological T stage			0.02
T1/T2	17 (89)	8 (44)
T3	2 (11)	10 (56)
AJCC TNM stage			0.02
I/II	17 (89)	8 (44)
III	2 (11)	10 (56)
ISUP grade			0.93
2/3	15 (79)	14 (78)
4	4 (21)	4 (22)
Necrosis			0.64
no	13 (68)	11 (61)
yes	6 (32)	7 (39)
Vascular invasion			0.58
no	17 (89)	15 (83)
yes	2 (11)	3 (17)

In the validation TCGA cohort (n=451), similar mutations frequencies were noted, including VHL in 50% of patients/samples, PBRRM1 in 29%, SETD2 in 11%, BAP1 in 9%, MTOR in 7%, KDM5C in 6%, PTEN in 4%, and ATM in 2.7%, respectively (Figure 1). Larger and higher stage tumors, particularly T3a, T3b, and stage III tended to have a higher frequency of non-VHL mutations (p=0.282; q=0.437) (Figure 2).

Figure 1. Frequency of mutated genes in primary ccRCC tumors (validation cohort, n=451).

Figure 2. Associations between histopathological characteristics and mutational profile (validation cohort, n=451).

Mutations in non-VHL genes predict recurrence

No recurrences were noted in patients with unmutated tumors or VHL-only mutations whereas three patients (17%) with other somatic mutations relapsed (p=0.06) (Table 4). Another three patients received and completed adjuvant PD-1 inhibition with pembrolizumab until present, none of whom recurred despite the presence of PBRM1 and SETD2 mutations in 2/3 and 1/3, respectively. Presence of somatic mutations in PBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, or PTEN genes in 451 TCGA ccRCC patients was associated with a significantly shorter DFS compared to those with unaltered tumors (p<0.001; q=0.01) (Figure 3).

Table 4. Associations of mutational profile (none or VHL-only versus non-VHL mutated genes) and disease recurrence.

Outcome	Mutated genes		P value
Outcome	None or VHL-only	Non-VHL	P value
Recurrence			0.06
no	19 (100)	15 (83)
yes	0 (0)	3 (17)

Figure 3. Kaplan-Meier analysis of DFS in patients with unmutated or VHL-only versus non-VHL mutated tumors (validation cohort, n=451).

Discussion

This ongoing prospective study examined the mutational profile of patients with ccRCC on primary tumors after nephrectomy followed by observation or adjuvant immunotherapy with pembrolizumab and assessed for associations of mutated genes with high-risk features and DFS. In this preliminary analysis of the first 37 patients, non-VHL mutations, including mutations in PBRM1, SETD2, BAP1, KDM5C, MTOR, PTEN, or ATM genes in a targeted 15-gene NGS panel were significantly associated with more aggressive histopathological characteristics including larger size, and higher stage. Presence of mutations in any of those genes as opposed to completely unmutated or VHL-only mutated tumors was also associated with higher ISUP grade, necrosis, sarcomatoid differentiation, vascular invasion and predicted recurrence. In ccRCC tumors from TCGA, non-VHL mutations in the same genes were also associated with high-risk features and predicted a significantly shorter DFS compared to VHL-only mutations or complete absence thereof.

The tumor suppressor VHL is the most frequently mutated gene in ccRCC and is a major player in renal cell carcinogenesis. However, VHL mutations alone are insufficient to drive disease progression.¹¹ Mounting evidence has revealed an emerging role of other genes, heavily involved in chromatin rearrangement and epigenetic DNA modifications, including PBRM1, SETD2, BAP1, and KDM5C in ccRCC progression.¹²^,¹³ Inactivating mutations or/and low expression of these genes in primary renal tumors have been associated with poor outcomes.¹⁴^–²⁰

Due to the retrospective nature of these studies and lack of reproducibility, particularly across immunohistochemical assessments²¹^,²² in an era when observation was the only available modality post-operatively even in high-risk patients, there has been a paucity of data to support testing of these genes as a molecular tool to assist in selection of patients who might benefit from adjuvant therapy.

Our ongoing prospective study addresses this gap by demonstrating that patients who had either no mutation or mutations in the most frequently altered gene, VHL, were more likely to have smaller tumors and experienced a more benign course without relapse, compared to those patients with tumors that harbored mutations in other genes, including PBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, or PTEN. Thus, this study suggests that patients with mutations in these high-risk genes might be more suitable candidates and should be prioritized for post-operative immunotherapy.

Our study was limited by small size and relatively short follow-up of patients. Nevertheless, presence of an early “signal” of high-risk genes in this preliminary report will be further studied in additional patients being accrued as part of this ongoing prospective study.

Data availability

Underlying data

figshare: F1000Res_Vlachostergios et al_raw data (subm).xlsx. https://doi.org/10.6084/m9.figshare.23697252.v1.²³

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Data from the validation TCGA cohort analyzed in this study are available from cbioportal.org, http://www.cbioportal.org/study/summary?id=kirc_tcga.

References

1. Shuch B, Amin A, Armstrong AJ, et al.: Under-standing pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur. Urol. 2015; 67: 85–97. PubMed Abstract | Publisher Full Text
2. Hsieh JJ, Purdue MP, Signoretti S, et al.: Renal cell carcinoma. Nat. Rev. Dis. Primers. 2017; 3: 17009. PubMed Abstract | Publisher Full Text | Free Full Text
3. Bray F, Ferlay J, Soerjomataram I, et al.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68: 394–424. PubMed Abstract | Publisher Full Text
4. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499: 43–49. PubMed Abstract | Publisher Full Text | Free Full Text
5. Li Y, Lih TM, Dhanasekaran SM, et al.: Clinical Proteomic Tumor Analysis Consor-tium. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell. 2023; 41: 139–163.e17. PubMed Abstract | Publisher Full Text | Free Full Text
6. Leibovich BC, Blute ML, Cheville JC, et al.: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003; 97: 1663–1671. Publisher Full Text
7. Correa AF, Jegede O, Haas NB, et al.: Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. J. Clin. Oncol. 2019; 37: 2062–2071. PubMed Abstract | Publisher Full Text | Free Full Text
8. Cosso F, Roviello G, Nesi G, et al.: Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope? Int. J. Mol. Sci. 2023; 24: 4243. PubMed Abstract | Publisher Full Text | Free Full Text
9. Choueiri TK, Tomczak P, Park SH, et al.: Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N. Engl. J. Med. 2021; 385: 683–694. Publisher Full Text
10. Papathanassiou M, Vlachostergios P: DNA library preparation for Ion Torrent S5 sequencing.Publisher Full Text
11. Ricketts CJ, De Cubas AA, Fan H, et al.: The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018; 23: 313–326.e5. PubMed Abstract | Publisher Full Text | Free Full Text
12. de Cubas AA , Rathmell WK: Epigenetic modifiers: activities in renal cell carcinoma. Nat. Rev. Urol. 2018; 15: 599–614. PubMed Abstract | Publisher Full Text | Free Full Text
13. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al.: BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 2012; 44: 751–759. PubMed Abstract | Publisher Full Text | Free Full Text
14. Hakimi AA, Ostrovnaya I, Reva B, et al.: Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 2013; 19: 3259–3267. PubMed Abstract | Publisher Full Text | Free Full Text
15. Joseph RW, Kapur P, Serie DJ, et al.: Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. J. Urol. 2016; 195: 180–187. PubMed Abstract | Publisher Full Text | Free Full Text
16. Kapur P, Peña-Llopis S, Christie A, et al.: Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013; 14: 159–167. PubMed Abstract | Publisher Full Text | Free Full Text
17. Liu W, Fu Q, An H, et al.: Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma. Medicine (Baltimore). 2015; 94: e2004. Publisher Full Text
18. Ohsugi H, Yoshida T, Ohe C, et al.: The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma. Ann. Surg. Oncol. 2021; 28: 2359–2366. PubMed Abstract | Publisher Full Text
19. da Costa WH , Rezende M, Carneiro FC, et al.: Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. BJU Int. 2014; 113: E157–E163. PubMed Abstract | Publisher Full Text
20. Santos VE, da Costa WH , Bezerra SM, et al.: Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma. Clin. Genitourin. Cancer. 2021; 19: 339–345. PubMed Abstract | Publisher Full Text
21. Kim SH, Park WS, Park EY, et al.: The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry. PLoS One. 2017; 12: e0179610. PubMed Abstract | Publisher Full Text | Free Full Text
22. Nishikawa M, Miyake H, Harada K, et al.: Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy. Urol. Oncol. 2014; 32(49): 49.e15–49.e21. PubMed Abstract | Publisher Full Text
23. Vlachostergios PJ: F1000Res_Vlachostergios et al_raw data (subm).xlsx. figshare. Figure. 2023. Publisher Full Text

Comments on this article Comments (0)

Version 2

VERSION 2 PUBLISHED 01 Aug 2023